TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05330585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aids
Description: Participants will listen to stimuli in the environment while wearing hearing aids which should make the stimuli more audible. Speech in noise performance is expected to improve and PFC oxygenation is expected to be reduced in this condition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unaided
Description: Participants will listen to stimuli in the environment with their hearing loss. Speech in noise performance is expected to decline and PFC oxygenation is expected to be increased in this condition.
Study: NCT04895488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: First treatment phase: vortioxetine will be initiated at 10 mg / day for 2 weeks, followed by 20 mg /day for 22 weeks. The dose of vortioxetine can be lowered to 5 mg or 10 mg for tolerability reasons at clinician criteria.~Wash-out period 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vortioxetine
Description: First treatment phase: vortioxetine will be initiated at 10 mg / day for 2 weeks, followed by 20 mg /day for 22 weeks. The dose of vortioxetine can be lowered to 5 mg or 10 mg for tolerability reasons at clinician criteria.~Wash-out period 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Usual Antipsychotic Treatment
Description: Second treatment phase. Usual antipsychotic treatment for 26 weeks: Allows for whatever medication, routine support, or referral to other services was felt appropriate by the clinician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Antipsychotic Treatment
Description: Second treatment phase. Usual antipsychotic treatment for 26 weeks: Allows for whatever medication, routine support, or referral to other services was felt appropriate by the clinician.
Study: NCT05203198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Competent Adulthood Transition with Cognitive-Behavioral, Humanistic and Interpersonal Training
Description: Self-directed, technology-based, depression prevention program for adolescents and parents.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Competent Adulthood Transition with Cognitive-Behavioral, Humanistic and Interpersonal Training
Description: Self-directed, technology-based, depression prevention program for adolescents and parents.
Study: NCT05849324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Straight needle
Description: Lumbar transforaminal epidural steroid injection is a useful option in the diagnosis and treatment of lumbar radicular pain. During lumbar transforaminal epidural steroid injection, straight needle is going to be used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bent needle
Description: Lumbar transforaminal epidural steroid injection is a useful option in the diagnosis and treatment of lumbar radicular pain. During lumbar transforaminal epidural steroid injection, bent needle is going to be used.
Study: NCT05834023

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-Lidocaine
Description: Infraclavicular block with 35 ml of the following anesthetic solution: Bupivacaine 0.25% + Lidocaine 1% + dexamethasone 4 mg + epinephrine 5 mcg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Infraclavicular block with 35 ml of the following anesthetic solution: Bupivacaine 0.5% + dexamethasone 4 mg + epinephrine 5 mcg/ml
Study: NCT05203198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Competent Adulthood Transition with Cognitive-Behavioral, Humanistic and Interpersonal Training
Description: Self-directed, technology-based, depression prevention program for adolescents and parents.
Study: NCT04950062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: 1. Warming up period for 5 min at an intensity corresponding to 65-75% of heart rate maximum (HRmax).~2. Training phase for 30 min divided into four sets of 4-min length each at intensity equals 80-90% of HRmax interspersed by 3 minutes low intensity walking at the level of 65-75% of HRmax.~3. Cooling down period for 5 min of at 50-60% of the HRmax. All subjects will be trained at the lower intensity limit for the first 2 weeks of the program before increasing the intensity levels toward the upper limit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Fasting 16/8 Protocol
Description: Every subject will be instructed to fast a fixed 16 hours followed by 8 hours of eating every day through the whole study period based on their life and sleeping style. During fasting, zero-calorie coffee, tea and water intake will be permitted. Beverages containing calories were consumed during the feeding hours each day. All subjects will be instructed about their optimum caloric requirement based on their basal metabolic rate that will be calculated in advance to avoid over consumption of food on severe caloric restriction as we like to investigate the effect of this way of fasting on reducing weight and improving functional capacity.
Study: NCT06544447

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: taVNS
Description: taVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients. Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water.~The electrodes were placed on the cymba conchae and concha around the affected ear, which is the region of rich vagus nerve branch distribution. Patients in control group were applied using the same stimulator, stimulation parameters and same sessions. However, the electrodes were placed on the antihelix around the affected ear, which is the region of few vagus nerve branch distribution.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS
Description: taVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients. Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water.~The electrodes were placed on the cymba conchae and concha around the affected ear, which is the region of rich vagus nerve branch distribution. Patients in control group were applied using the same stimulator, stimulation parameters and same sessions. However, the electrodes were placed on the antihelix around the affected ear, which is the region of few vagus nerve branch distribution.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Hyaluronic acid eye drops
Description: Participants in both groups received hyaluronic acid eye drops (HYLO COMOD® eye drops, Ursapharm, Ltd., Germany) with the treatment of 3 times a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid eye drops
Description: Participants in both groups received hyaluronic acid eye drops (HYLO COMOD® eye drops, Ursapharm, Ltd., Germany) with the treatment of 3 times a day.
Study: NCT06145789

Intervention type: OTHER
Intervention: standing powered wheelchair evaluation
Description: standing powered wheelchair evaluation
Study: NCT05726266

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Patients will listen daily to a musical playlist for 30 - 60 minutes in a row; the psychologist will set up a music playlist according to the patient's individual interests. Patients will be asked to focus on this activity, that is, without performing any other activity simultaneously.
Study: NCT05743062

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual reality intervention will be given 6 times in total and each session will last not more than 60 seconds. Participants will be asked to fill out a survey before the intervention to collect the baseline data, after each session of VR intervention and a final survey at the end of the study.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: For case control, participants will service as their self control and no VR intervention will be given at first. Participants will be asked to fill out a survey before the intervention to collect the baseline data.
Study: NCT05726266

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Audiobook
Description: Patients will listen daily to an audiobook for 30 - 60 minutes in a row; the psychologist will set up a list of audiobooks according to the patient's individual interests. Patients will be asked to focus on this activity, that is, without performing any other activity simultaneously.
Study: NCT05158283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: chocolate balloon
Description: chocolate balloon dilatation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: plain balloon
Description: plain balloon dilatation
Study: NCT04813497

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serology to determine SARS-CoV-2 infection
Description: Each participant accept to have two blood tests on a dry tube of maximum 8 ml of whole blood

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serology to determine SARS-CoV-2 infection
Description: Each participant accept to have two blood tests on a dry tube of maximum 8 ml of whole blood

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serology to determine SARS-CoV-2 infection
Description: Each participant accept to have two blood tests on a dry tube of maximum 8 ml of whole blood

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serology to determine SARS-CoV-2 infection
Description: Each participant accept to have two blood tests on a dry tube of maximum 8 ml of whole blood

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serology to determine SARS-CoV-2 infection
Description: Each participant accept to have two blood tests on a dry tube of maximum 8 ml of whole blood
Study: NCT05501756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab (Campath®) is a recombinant DNA-derived humanized monoclonal antibody directed against CD52. Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Neomycin is not detectable in the final product. Alemtuzumab is a sterile, clear, colorless, isotonic pH 6.8-7.4 solution for injection. Alemtuzumab is supplied in single-use clear glass ampules containing 30 mg of Alemtuzumab in 3 mL of solution. A single use vial of alemtuzumab contains 30 mg alemtuzumab, 8 mg sodium chloride, 1.44 mg dibasic sodium phosphate, 0.2 mg potassium chloride, 0.2 mg monobasic potassium phosphate, 0.1 mg polysorbate 80, and 0.0187 mg disodium edetate dihydrate.
Study: NCT06455345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-Guided Online ACT Program
Description: Participants will be invited to access the ACT program on the Manage My Pain (MMP) app. Participants will follow the instructions in the app to complete the program in a self-paced manner. The program includes psychoeducational materials, guided mindfulness meditations, and self-reflection activities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Participants will be invited to join a one-session ACT group workshop guided by a psychologist. The session will take place virtually using video call software. The psychologist will guide participants through the workshop agenda, which will include psychoeducational material, guided mindfulness meditations, and partaking in voluntary discussions with other group members.
Study: NCT04720625

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapt2Quit
Description: Motivational text messages and quitline facilitation text messages will be sent to participants; these participants will receive Adapt2Quit (experimental) messages as well as quitline facilitation messages.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Quitline facilitation text messages will be sent to participants; these participants will receive quitline facilitation-only messages.
Study: NCT04721899

Intervention type: DIETARY_SUPPLEMENT
Intervention: Vitamin D
Description: Vitamin D 50,000 IU once per week for 4 weeks, followed by 50,000 IU once every 2 weeks for 4 weeks
Study: NCT05721183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NOST
Description: The intervention is to implement NOST, which includes:~observation and recording of compliance with hand hygiene recommendations identification of areas for improvement training or other actions taken to improve IPC in general or compliance with hand hygiene.~Thus, the intervention includes both observation of compliance and any additional improvement measures initiated as a result of the introduced NOST.~When the intervention group has implemented and followed NOST for a year, the investigators will measure compliance with hand hygiene recommendations and reported HAIs, in wards that have had NOST and in wards that have not introduced NOST.~The intervention arm will be followed over time with repeated measurements of both compliance with hand hygiene and other outcome measures, to see if the effect increases in line with implemented observations and quality improvement measures, or if the effect decreases during the study period.
Study: NCT06257160

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical infiltration
Description: During surgery, local anesthetics are injected as follow: in the deep plane and in the subcutaneous territory.~Infiltration of the deep plane corresponds to pericotyloid injection, with particular attention to the posterior subcapsular area, the obturator foramen and the psoas muscle. Infiltration of the muscular planes is added, with infiltration of the gluteal and pelvitrochanteric muscles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG Block ultrasound-guided
Description: We perform the femoral block under ultrasound after anesthesia (general or rachianesthesia). The PENG block is a peripheral diffusion nerve block that specifically targets the articular divisions of the femoral, obturator and accessory obturator nerves.~The femoral nerve innervates the four parts of the joint capsule, with inconsistency in the anterior inferomedial part of the capsule.~The obturator nerve innervates the inferior part of the anterior face of the capsule.~The accessory obturator nerve innervates the medial half of the hip joint capsule in over 50% of cases.
Study: NCT06176469

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05994053

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high definition transcranial alternating current stimulation
Description: low intensity alternating current to OFC

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: high definition transcranial alternating current stimulation
Description: low intensity alternating current to OFC
Study: NCT05872880

Intervention type: PROCEDURE
Intervention: Modified radical surgery
Description: The modified radical surgery was performed within 4 to 6 weeks after the end of the last chemotherapy, and local extended resection was performed according to the scope of the residual tumor lesions after induction therapy: the incisal margin was 1 to 1.5cm outside the boundary of the residual tumor lesions, and multi-point incisal rapid disease detection was performed intraoperatively to ensure negative incisal margin and complete resection of the residual tumor lesions. Under this premise, the surgical trauma should be minimized, and the organs and appearance of the patient should be preserved. For example, facial skin should not be penetrated, mandible should not be cut off, and tongue tissue should be preserved as much as possible. Direct suture or local tissue flap should be used to repair the defect during the operation. At the same time, improved radical neck dissection was performed on the affected side of the neck.

Intervention type: PROCEDURE
Intervention: Radical surgery
Description: Radical surgery was performed within 4 to 6 weeks after the end of the last chemotherapy, and a wide range of radical surgical resection was performed according to the tumor scope before induction therapy: the incisal margin was 1 to 1.5cm outside the tumor boundary before induction, the lower lip and mandible could be incised if necessary, the facial skin could be excised, the mandibular bone segmentectomy was feasible, and pedicle or free skin (bone) flap was used to repair the defect. At the same time, improved radical neck dissection was performed on both sides of the affected neck.
Study: NCT04788186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: De-prescribe beta blocker therapy
Description: Participants will be de-prescribed for beta-blocker therapy.~De-prescription will be performed as follows:~* Half of pre-randomization dose for the first 3 days, then~* Half of the above dose for the next 3 days, then discontinue
Study: NCT05704179

Intervention type: OTHER
Intervention: Obstetric Quality of recovery score
Description: Patients' quality of recovery will be evaluated with Obstetric Quality of recovery score (ObsQoR-11) on postpartum day 1 and day 2.
Study: NCT04951713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3287 combined with clarithromycin
Description: Drug: XZP-3287, oral, 120 mg once daily for day 1 and day 12 Drug: clarithromycin, oral, 500 mg twice daily for day 8 to day 21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3287 combined with rifampicin
Description: Drug: XZP-3287, oral, 360 mg once daily for day 1 and day 14 Drug: rifampicin, oral, 600 mg once daily for day 8 to day 19
Study: NCT06215144

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NRCT-101SR
Description: NRCT-101SR is a sustained release formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRCT-101SR
Description: NRCT-101SR is a sustained release formulation.
Study: NCT04721899

Intervention type: DIETARY_SUPPLEMENT
Intervention: Vitamin D
Description: Vitamin D 50,000 IU once per week for 4 weeks, followed by 50,000 IU once every 2 weeks for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Intervention: Vitamin D
Description: Vitamin D 50,000 IU once per week for 4 weeks, followed by 50,000 IU once every 2 weeks for 4 weeks
Study: NCT05724199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Description: Subcutaneous (SC) injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection
Study: NCT05269589

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Thermoneutral water
Description: Participants will immerse their feet in a foot bath that contains thermoneutral water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot water
Description: Participants will immerse their feet in a foot bath that contains hot water
Study: NCT04542434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide Oral Tablet
Description: Niclosamide tablets 400 mg 3 times daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets 3 times daily for 14 days
Study: NCT06350786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P-Dragees blue Lichtenstein, Placebo dragees
Description: In the intervention group, open-label placebos are administered within the framework of a mind-body management intervention approach, which in turn is consistent with the biopsychosocial model of pain and with a patient-centred approach. The verbal interaction follows the four discussion points:~1. Opioids work by telling the body that participants are not experiencing as much pain;~2. Placebos should be taken every time an opioid is taken which supports the reduction of opioid medication (shown by previous studies);~3. By pairing the pills together the brain will learn to release chemicals like endorphins that cause pain-relief in response to the placebo, just as it does in response to the opioid;~4. At a certain point, placebos might provide adequate pain relief, and the participants might need less opioids.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group (EM)
Description: In the EM control group, the focus lies on the electronic monitoring (EM) of the opioid intake. The treatment rationale is designed to facilitate the reduction of opioid medication by promoting a positive attitude towards the implementation of the reduction. The verbal interaction follows the four discussion points:~1. The collection of EM data allows for greater patients' sense of agency over medication treatment;~2. Tracking of opioid medication use supports the reduction of opioid medication (shown by previous studies);~3. The EM is a useful tool, and daily recording of opioid medication intake should be done;~4. At a certain point, EM might provide adequate pain relief, and participants might need less opioids.
Study: NCT05441891

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auditory intervention filter-modulated group
Description: Intervention consisted of listening to classical music modulated by an equalizer for 30 minutes, 2 sessions a day separated by at least 3 hours, for 10 days (Monday to Friday for 2 weeks).~The musical intervention was always performed with the same songs and in the same order using original CDs, heard through headphones (Beyerdynamic, DT 250 / 80 ohm. GMBH \& Co. KG, Theresienstr. 8 D-74072 Heilbronn, Germany). The music was played with a sound system (Panasonic MASH, No. SA-PM24. Hamburg, Germany). and filtered through an equalizer called Earducator (Hollagen Designs, PÍO. Box 43 7864 Bergvliet W.Cape - South Africa) that modulates music by alternating low and high tones with an unpredictable cadence, preventing habituation. It also allows very narrow band complementary filters to attenuate (by about 40 dB) abnormally perceived frequencies (hyper-hearing peaks): filters in: 1 kHz - 1,5 kHz - 2kHz - 3 kHz - 4 kHz - 8kHz.
Study: NCT05031377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HE programme
Description: Participants will receive a 12-week integrated exercise and cardiovascular health education programme (HE programme) which is constructed based on self-efficacy theory. A booster intervention in the form of SMS messaging will be given from Week 1 to Week 12.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Usual care
Description: Participants will receive usual care which primarily includes an education talk on basic health issues. Governmental health education leaflets will be provided for reference.